Lake Street assumed coverage of P3 Health Partners (PIII) with a Buy rating and $20 price target Despite first half revenue declining versus the prior year, Q2 results showed “encouraging signs,” the analyst tells investors. 2025 remains a transitional year as the P3 sets up for a “transformational 2026,” the analyst added.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PIII: